Reposted from Pharmacy Choice
Findings from Sheba Medical Center in Pancreatic Cancer Provides New Insights (Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer)
By a News Reporter-Staff News Editor at Cancer Weekly Investigators publish new report on Oncology – Pancreatic Cancer. According to news reporting out of Ramat Gan, Israel, by NewsRx editors, research stated, “BRCA1/BRCA2 germ line (GL) mutation carriers with pancreatic adenocarcinoma (PDAC) may have distinct outcomes. We recently described an apparent more favourable prognosis of surgically resected BRCA-associated PDAC patients in a single-arm, uncontrolled, retrospective study.”
Our news journalists obtained a quote from the research from Sheba Medical Center, “However, the prognostic impact of GL BRCA1/2 mutations in surgically resected PDAC has not been compared with a matched control population. A larger multi-centre, case-control retrospective analysis was performed. Cases were patients with surgically resected, BRCA1/2-associated PDAC from 2004 to 2013. Controls included surgically resected PDAC cases treated during the same time period that were either BRCA non-carriers, or had no family history of breast, ovarian or pancreatic cancers. Cases and controls were matched by: age at diagnosis (within ?5-year period) and institution. Demographics, clinical history, overall survival (OS) and disease-free survival (DFS) were abstracted from patient records. Statistical comparisons were assessed using ch-and Fisher’s exact test, and median DFS/OS using Kaplan-Meier method and log-rank testing. Twenty-five patients with BRCA1-(n=4) or BRCA2 (N=21)-associated resectable PDAC were identified. Mean age was 55.7 years (range, 34-78 years), 48% (n=12) were females and 76% (n=19) were Jewish. Cases were compared (1 : 2) with 49 resectable PDAC controls, and were balanced for age, ethnicity and other relevant clinical and pathological features. BRCA-associated PDAC patients received neoadjuvant, or adjuvant platinum-based treatment more frequently than controls (7 out of 8 vs 6 out of 14) and (7 out of 21 vs 3 out of 44), respectively. No significant difference in median OS (37.06 vs 38.77 months, p=0.838) and in DFS (14.3 vs 12.0 months, p=0.303) could be demonstrated between cases and controls. A trend to increased DFS was observed among BRCA-positive cases treated with neoadjuvant/adjuvant platinum-containing regimens (n=10) compared with similarly treated controls (n=7) (39.1 vs 12.4 months, p=0.255). In this retrospective analysis, the prognosis of surgically resectable BRCA-associated PDAC is no different than that of sporadic PDAC from the same institution.”
According to the news editors, the research concluded: “The role of platinum-based adjuvant therapy in this setting requires prospective investigation.British Journal of Cancer (.”
For more information on this research see: Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer. British Journal of Cancer, 2017;():. (Nature Publishing Group – www.nature.com/; British Journal of Cancer – www.nature.com/bjc/)
Our news journalists report that additional information may be obtained by contacting T. Golan, Dept. of Oncology, Sheba Medical Center, Ramat Gan 52621, Israel. Additional authors for this research include T. Sella, E.M. O’Reilly, M.H. Katz, R. Epelbaum, D.P. Kelsen, A. Borgida, H. Maynard, H. Kindler, E. Friedmen, M. Javle and S. Gallinger (see also Oncology – Pancreatic Cancer).
Keywords for this news article include: Asia, Israel, Genetics, Oncology, Ramat Gan, Epidemiology, Gastroenterology, Pancreatic Cancer, Pancreatic Neoplasms.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC